Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 226,500 |
50 mg | 約6-8 週間 | ¥ 301,000 |
100 mg | 約6-8 週間 | ¥ 457,000 |
説明 | CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol. |
In vitro | CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons. CP-532623 is highly lymphatically transported (28% of the dose). However, it lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions. But, it has poorly related to solubility in mixtures of lipoprotein core and/or surface lipids [2]. |
In vivo | CP-532623 (50 mg; p.o.; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively) [3]. |
分子量 | 598.5 |
分子式 | C27H27F9N2O3 |
CAS No. | 261947-38-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CP-532623 261947-38-0 Metabolism CETP CP532623 CP 532623 Inhibitor inhibitor inhibit